Spero Therapeutics, Inc. Increase (Decrease) in Income Taxes Payable
Spero Therapeutics, Inc. (SPRO) reported Increase (Decrease) in Income Taxes Payable of -$220.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable · last filed 2026-08-12
- Spero Therapeutics, Inc. increase (decrease) in income taxes payable for the quarter ending 2026-06-30 was $0.00.
- Spero Therapeutics, Inc. increase (decrease) in income taxes payable for the quarter ending 2026-03-31 was -$220.00K.
- Spero Therapeutics, Inc. increase (decrease) in income taxes payable for the quarter ending 2025-12-31 was $220.00K, a 185.71% increase year-over-year.
- Spero Therapeutics, Inc. increase (decrease) in income taxes payable for the quarter ending 2025-09-30 was $0.00.
- Spero Therapeutics, Inc. increase (decrease) in income taxes payable for fiscal 2025 was $209.00K.
- Spero Therapeutics, Inc. increase (decrease) in income taxes payable for fiscal 2024 was -$213.00K, a 155.04% decline from fiscal 2023.
- Spero Therapeutics, Inc. increase (decrease) in income taxes payable for fiscal 2023 was $387.00K.
- Spero Therapeutics, Inc. increase (decrease) in income taxes payable for fiscal 2022 was $0.00.
| Period end | Increase (Decrease) in Income Taxes Payable 3 month | Increase (Decrease) in Income Taxes Payable 6 month | Increase (Decrease) in Income Taxes Payable 9 month | Increase (Decrease) in Income Taxes Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$220.00K 10-Q · filed 2026-08-12 | $0.00 derived: sum of 3 quarters · filed 2026-08-12 | $0.00 derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$220.00K 10-Q · filed 2026-05-13 | $0.00 derived: sum of 2 quarters · filed 2026-05-13 | $0.00 derived: sum of 3 quarters · filed 2026-05-13 | -$11.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $220.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $220.00K derived: sum of 2 quarters · filed 2026-03-26 | $209.00K derived: sum of 3 quarters · filed 2026-08-12 | $209.00K 10-K · filed 2026-03-26 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$11.00K derived: sum of 2 quarters · filed 2026-08-12 | -$11.00K 10-Q · filed 2025-11-13 | $66.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$11.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$11.00K 10-Q · filed 2026-08-12 | $66.00K derived: sum of 3 quarters · filed 2026-08-12 | -$224.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-13 | $77.00K derived: sum of 2 quarters · filed 2026-05-13 | -$213.00K derived: sum of 3 quarters · filed 2026-05-13 | |
| 2024-12-31 | $77.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$213.00K derived: sum of 2 quarters · filed 2026-03-26 | -$213.00K 10-K · filed 2026-03-26 | |
| 2024-09-30 | -$290.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$290.00K 10-Q · filed 2025-11-13 | ||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-12 | |||
| 2023-12-31 | -$1.82M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $387.00K 10-K · filed 2025-03-27 | ||
| 2023-09-30 | $2.21M 10-Q · filed 2024-11-14 | |||
| 2022-12-31 | $0.00 10-K · filed 2024-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 |